# Unveiling the Therapeutic Potential of “Taikong Blue” Lavender Essential Oil and Its Key Compounds in Skin Problems via Network Pharmacology and In Vitro Validation

**Authors:** Fei Liu, Yingyu Zhang, Minhazul Abedin, Jingyi Song, Suzhen Yang, Hongxiang Lou, Xixi Dou, Junsong Xiao, Hua Wu

PMC · DOI: 10.1111/jocd.70640 · Journal of Cosmetic Dermatology · 2026-01-28

## TL;DR

This study explores how 'Taikong Blue' lavender essential oil helps with skin issues by combining network pharmacology and lab experiments.

## Contribution

The study identifies key compounds and molecular mechanisms of TLEO in treating inflammatory skin conditions.

## Key findings

- TLEO reduces oxidative stress and inflammation in TNF-α-stimulated HaCaT cells.
- Linalool and linalyl acetate show moderate binding to targets like MMP9, EGFR, and PTGS2.
- TLEO inhibits p38 MAPK and NF-κB p65 phosphorylation, restoring skin barrier function.

## Abstract

Taikong Blue Lavender Essential Oil (TLEO) is derived from a proprietary space‐bred cultivar of 
Lavandula angustifolia
 and cultivated under pristine conditions in Xinjiang, China. TLEO has long been used by regional people to treat various skin disorders such as hyperpigmentation, trans‐epidermal water loss, collagen degradation, and poor wound healing. Despite the ethnopharmacological applications of TLEO, the molecular basis of its dermatological efficacy remains poorly defined.

This study integrated network pharmacology, molecular docking, and in vitro assays to systematically investigate how TLEO works against inflammatory skin conditions, focusing on its key compounds and biological targets.

A total of 66 skin disorder‐related genes were identified through network pharmacology, with gene enrichment analyses highlighting the TNF signaling pathway as a critical mediator. Protein–protein interaction analysis revealed MMP9, EGFR, and PTGS2 as core targets. Molecular docking confirmed that linalool and linalyl acetate, the primary constituents of TLEO, exhibited moderate binding affinities with these targets. In vitro experiments using TNF‐α‐stimulated HaCaT cells demonstrated that treatment with 0.01% TLEO significantly (p < 0.05) reduced oxidative stress markers (NO, ROS, MDA), restored antioxidant enzymes (SOD, CAT), and downregulated inflammatory cytokines (IL‐6, IL‐1β, IL‐8). TLEO also inhibited the phosphorylation of p38 MAPK and NF‐κB p65, suppressed PTGS2 and MMP9 expression, and restored EGFR levels, indicating anti‐inflammatory and barrier‐restorative functions.

The study establishes a scientific foundation for the use of TLEO as a multifunctional ingredient in dermatological applications and highlights its value as a sustainable crop for regional economic development in Xinjiang.

## Linked entities

- **Genes:** MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318], EGFR (epidermal growth factor receptor) [NCBI Gene 1956], PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743], SOD1 (superoxide dismutase 1) [NCBI Gene 6647], CAT (catalase) [NCBI Gene 847], IL6 (interleukin 6) [NCBI Gene 3569], IL1B (interleukin 1 beta) [NCBI Gene 3553], CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576], P38mapk (p38 map kinase) [NCBI Gene 692545]
- **Chemicals:** linalool (PubChem CID 6549), linalyl acetate (PubChem CID 8294), NO (PubChem CID 24822), MDA (PubChem CID 1614)
- **Species:** Lavandula angustifolia (taxon 39329)

## Full-text entities

- **Genes:** ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, CAT (catalase) [NCBI Gene 847], MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, SELE (selectin E) [NCBI Gene 6401] {aka CD62E, ELAM, ELAM1, ESEL, LECAM2, selectin-e}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}
- **Diseases:** atherosclerosis (MESH:D050197), atopic dermatitis (MESH:D003876), depression (MESH:D003866), epidermal (MESH:D004814), psoriasis (MESH:D011565), water loss (MESH:D000069578), eczema (MESH:D004485), hyperpigmentation (MESH:D017495), Skin Disease (MESH:D012871), inflammation (MESH:D007249), anxiety (MESH:D001007), acne (MESH:D000152), cutaneous irritation (MESH:D001523), TLEO (MESH:D018329), premature aging (MESH:D019588), dryness (MESH:D014987), cytotoxicity (MESH:D064420)
- **Chemicals:** Essential Oil (MESH:D009822), esters (MESH:D004952), DCFH-DA (MESH:C029569), penicillin (MESH:D010406), adalimumab (MESH:D000068879), streptomycin (MESH:D013307), CB (MESH:C063451), ROS (MESH:D017382), carnosic acid (MESH:C018381), PVDF (MESH:C024865), PBS (MESH:D007854), doxycycline (MESH:D004318), CO2 (MESH:D002245), MDA (MESH:D015104), CCK-8 (MESH:D012844), alcohols (MESH:D000438), MDA (MESH:D008315), oils (MESH:D009821), hydrogen (MESH:D006859), SYBR Green (MESH:C098022), rosmarinic acid (MESH:C041376), water (MESH:D014867), LPS (MESH:D008070), lipids (MESH:D008055), SDS (MESH:D012967), NO (MESH:D009614), tacrolimus (MESH:D016559), diterpenes (MESH:D004224), prostaglandin (MESH:D011453), Linalool (MESH:C018584), 2',7'-dichlorodihydrofluorescein diacetate (MESH:C110400), Rosmarinus officinalis  oil (MESH:C053775), NO (MESH:D009569), Chemical (-), LEO (MESH:C045718), polyphenols (MESH:D059808), ceramide (MESH:D002518), monoterpenes (MESH:D039821), sesquiterpenes (MESH:D012717), Linalyl acetate (MESH:C074463), S (MESH:D013455), zinc (MESH:D015032), P (MESH:D010758)
- **Species:** Lavandula angustifolia (lavender, species) [taxon 39329], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12848645/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12848645/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12848645/full.md

---
Source: https://tomesphere.com/paper/PMC12848645